Thomas R. OʼBrien

10.3k total citations · 2 hit papers
126 papers, 5.4k citations indexed

About

Thomas R. OʼBrien is a scholar working on Epidemiology, Hepatology and Virology. According to data from OpenAlex, Thomas R. OʼBrien has authored 126 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Epidemiology, 61 papers in Hepatology and 39 papers in Virology. Recurrent topics in Thomas R. OʼBrien's work include Hepatitis C virus research (55 papers), Liver Disease Diagnosis and Treatment (43 papers) and Hepatitis B Virus Studies (41 papers). Thomas R. OʼBrien is often cited by papers focused on Hepatitis C virus research (55 papers), Liver Disease Diagnosis and Treatment (43 papers) and Hepatitis B Virus Studies (41 papers). Thomas R. OʼBrien collaborates with scholars based in United States, United Kingdom and Taiwan. Thomas R. OʼBrien's co-authors include James J. Goedert, Ruth M. Pfeiffer, Ludmila Prokunina‐Olsson, Stephen J. O’Brien, Philip S. Rosenberg, Katherine A. McGlynn, Mary Carrington, David Vlahov, Raymond P. Donnelly and Susan Buchbinder and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Thomas R. OʼBrien

122 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression

1997 721 citations Mary Carrington, James J. Goedert et al. profile →
Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures

1996 518 citations Thomas R. OʼBrien et al. profile →

Peers

Countries citing papers authored by Thomas R. OʼBrien

Since Specialization

Citations

This map shows the geographic impact of Thomas R. OʼBrien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas R. OʼBrien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas R. OʼBrien more than expected).

Fields of papers citing papers by Thomas R. OʼBrien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas R. OʼBrien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas R. OʼBrien. The network helps show where Thomas R. OʼBrien may publish in the future.

Co-authorship network of co-authors of Thomas R. OʼBrien

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas R. OʼBrien. A scholar is included among the top collaborators of Thomas R. OʼBrien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas R. OʼBrien. Thomas R. OʼBrien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C 2024 ·Journal of Infection ·Thomas R. OʼBrien, David Witt, Varun Saxena, (unknown), Sabrina Chen, (unknown), Ludmila Prokunina‐Olsson, Ruth M. Pfeiffer, (unknown)	0
2	Risk of hepatocellular carcinoma in people with HIV in the United States, 2001-2019 2023 ·JNCI Journal of the National Cancer Institute ·(unknown), (unknown), Eric A. Engels, Thomas R. OʼBrien, Marie‐Josèphe Horner, Baozhen Qiao, (unknown), Qianlai Luo, Meredith S. Shiels	7
3	Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort 2022 ·Cancers ·(unknown), (unknown), Sarah S. Jackson, Ruth M. Pfeiffer, Tram Kim Lam, Thomas R. OʼBrien, Kelly J. Yu, Katherine A. McGlynn, Jessica L. Petrick, Ligia A. Pinto, Chien‐Jen Chen, Allan Hildesheim, Hwai‐I Yang, Mei‐Hsuan Lee, Jill Koshiol	1
4	The role of IFNL4 in liver inflammation and progression of fibrosis 2022 ·Genes and Immunity ·(unknown), Thomas R. OʼBrien, Rune Hartmann	1
5	Death certificates compared to SEER‐Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection 2021 ·Journal of Viral Hepatitis ·Joy Jiang, Meredith S. Shiels, Thomas R. OʼBrien	3
6	Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus‐ and hepatitis C virus‐infected individuals 2021 ·Alimentary Pharmacology & Therapeutics ·Jill Koshiol, (unknown), Zhiwei Liu, Tram Kim Lam, Thomas R. OʼBrien, Kelly J. Yu, Katherine A. McGlynn, Jessica L. Petrick, Lígia A. Pinto, (unknown), Allan Hildesheim, Ruth M. Pfeiffer, Mei‐Hsuan Lee, Hwai‐I Yang	17
7	The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection 2021 ·Journal of Interferon & Cytokine Research ·(unknown), Ida Monrad, Line K. Vibholm, (unknown), Giacomo S. Frattari, Mariane Høgsbjerg Schleimann, Rikke Olesen, Mads Kjølby, Jesper Damsgaard Gunst, Ole S. Søgaard, Thomas R. OʼBrien, Martin Tolstrup, Rune Hartmann	2
8	COVID-19 and emerging viral infections: The case for interferon lambda 2020 ·The Journal of Experimental Medicine ·Ludmila Prokunina‐Olsson, (unknown), Ruth E. Dickenson, Joan E. Durbin, Jeffrey S. Glenn, Rune Hartmann, Sergei V. Kotenko, Helen M. Lazear, Thomas R. OʼBrien, Charlotte Odendall, Olusegun O. Onabajo, Helen Piontkivska, Deanna M. Santer, Nancy C. Reich, Andreas Wack, Ivan Zanoni	140
9	Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis 2018 ·Journal of Gastrointestinal Cancer ·Richard H. Lewis, Evan S. Glazer, (unknown), Thomas R. OʼBrien, Jeremiah L. Deneve, David Shibata, Stephen W. Behrman, Jason M. Vanatta, Sanjaya K. Satapathy, Paxton V. Dickson	7
10	Macroeconomics (3rd edition) 2015 ·Murdoch Research Repository (Murdoch University) ·(unknown), (unknown), Paul Lewis, Thomas R. OʼBrien	9
11	IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family 2014 ·Journal of Interferon & Cytokine Research ·Thomas R. OʼBrien, Ludmila Prokunina‐Olsson, Raymond P. Donnelly	118
12	IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin 2013 ·The Journal of Infectious Diseases ·Eric G. Meissner, Dimitra Bon, Ludmila Prokunina‐Olsson, Wei Tang, Henry Masur, Thomas R. OʼBrien, Eva Herrmann, Shyamasundaran Kottilil, A. Osinusi	76
13	Macroeconomics (2nd edition) 2012 ·Murdoch Research Repository (Murdoch University) ·(unknown), (unknown), Paul Lewis, Thomas R. OʼBrien	3
14	Microeconomics (2nd edition) 2012 ·Murdoch Research Repository (Murdoch University) ·(unknown), (unknown), Philip Lewis, Thomas R. OʼBrien	11
15	PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS 2011 ·Hepatology ·Alexander Thompson, Paul J. Clark, David M. Vock, Ruth M. Pfeiffer, Hans L. Tillmann, Keyur Patel, Susanna Naggie, Fred Poordad, Lisa M. Nyberg, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, David B. Goldstein, John G. McHutchison, Thomas R. OʼBrien, Mark Sulkowski, Andrew J. Muir	1
16	Hepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCV 2008 ·The Journal of Infectious Diseases ·Eishiro Mizukoshi, Christoph Eisenbach, Brian R. Edlin, Kimberly P. Newton, Sukanya Raghuraman, Christina Weiler‐Normann, Leslie H. Tobler, Michael P. Busch, Mary Carrington, Jane A. McKeating, Thomas R. OʼBrien, Barbara Rehermann	47
17	Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression 2003 ·AIDS ·(unknown), Thomas R. OʼBrien, John P. A. Ioannidis, James J. Goedert, Susan Buchbinder, Roel A. Coutinho, Beth D. Jamieson, Laurence Meyer, Nelson L. Michael, Giuseppe Pantaleo, G. Paolo Rizzardi, Hanneke Schuitemaker, Haynes W. Sheppard, Ioannis Theodorou, David Vlahov, Philip S. Rosenberg	78
18	Effect of CCR5-Δ32 Heterozygosity on the Risk of Perinatal HIV-1 Infection: A Meta-Analysis 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Despina G. Contopoulos‐Ioannidis, Thomas R. OʼBrien, James J. Goedert, Philip S. Rosenberg, John P. A. Ioannidis	18
19	Reporting, Appraising, and Integrating Data on Genotype Prevalence and Gene-Disease Associations 2002 ·American Journal of Epidemiology ·Julian Little, Linda Bradley, Molly S. Bray, Mindy Clyne, Janice S. Dorman, Darrell L. Ellsworth, Jennifer Hanson, Muin J. Khoury, J. Lau, Thomas R. OʼBrien, Nathaniel Rothman, Diane Stroup, Emanuela Taioli, David M. Thomas, Harri Vainio, Sholom Wacholder, Clarice R. Weinberg	293
20	HIV-1 and HIV-2 Infections Among U.S. Peace Corps Volunteers Returning from West Africa 1995 ·Journal of Travel Medicine ·Thomas R. Eng, Thomas R. OʼBrien, Kenneth Bernard, Charles A. Schable, (unknown), Scott D. Holmberg	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact